OTLK Stock Price, Outlook Therapeutics Inc Quote, Chart

Market Summary

USD8.58+0.08

Delayed

0.94%

OTLK Alerts

1 major insider buys recently.

OTLK Stock Price

View Fullscreen

OTLK RSI Chart

OTLK Valuation

Market Cap

111.7M

Price/Earnings (Trailing)

-2.17

Price/Sales (Trailing)

13.42

EV/EBITDA

-1.93

Price/Free Cashflow

-2.37

OTLK Price/Sales (Trailing)

OTLK Profitability

EBT Margin

-724.02%

Return on Equity

211.55%

Return on Assets

-237.48%

Free Cashflow Yield

-42.19%

OTLK Fundamentals

OTLK Revenue

Revenue (TTM)

8.1M

OTLK Earnings

Earnings (TTM)

-51.5M

Earnings Growth (Yr)

40.1%

Earnings Growth (Qtr)

13.95%

Breaking Down OTLK Revenue

Last 7 days

1.8%

Last 30 days

-5.9%

Last 90 days

2283.3%

Trailing 12 Months

673.0%

How does OTLK drawdown profile look like?

OTLK Financial Health

Current Ratio

0.44

Debt/Equity

0.03

Debt/Cashflow

-3.42

OTLK Investor Care

Shares Dilution (1Y)

1.40%

Diluted EPS (TTM)

-4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	3.3M	3.1M	8.1M	0
2018	4.7M	5.2M	3.1M	3.4M
2017	1.6M	1.4M	3.8M	4.3M
2016	3.8M	3.0M	3.0M	2.3M
2015	7.8M	6.5M	5.2M	3.3M
2014	0	0	9.1M	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Outlook Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	syntone ventures llc	bought	-	-	714,286	-
Mar 28, 2024	haddadin yezan munther	bought	22,241	11.82	1,881	-
Mar 18, 2024	sukhtian ghiath m.	acquired	-	-	2,305,710	-
Mar 07, 2024	evanson jeff	bought	26,243	0.42	62,484	chief commercial officer
Apr 20, 2023	dagnon terry	sold	-590,200	1.135	-520,000	chief operations officer
Jan 20, 2023	evanson jeff	sold	-296,370	1.11	-267,000	chief commercial officer
Jan 19, 2023	evanson jeff	sold	-125,971	1.22	-103,255	chief commercial officer
Jan 18, 2023	evanson jeff	sold	-42,172	1.25	-33,738	chief commercial officer
Jan 17, 2023	evanson jeff	sold	-35,582	1.31	-27,162	chief commercial officer
Dec 28, 2022	sukhtian ghiath m.	acquired	12,500,000	0.8784	14,230,400	-

Which funds bought or sold OTLK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	Solutions 4 Wealth, Ltd	sold off	-100	-12,922	-	-%
May 02, 2024	KESTRA PRIVATE WEALTH SERVICES, LLC	sold off	-100	-4,137	-	-%
May 02, 2024	LINCOLN NATIONAL CORP	sold off	-100	-24,940	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	53,790	53,790	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	sold off	-100	-34,034	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	11.00	11.00	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	sold off	-100	-7,618	-	-%
Apr 29, 2024	Crew Capital Management, Ltd.	sold off	-100	-7,880	-	-%

Are Funds Buying or Selling OTLK?

Are funds buying OTLK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OTLK

No. of Funds

OTLK Alerts

1 major insider buys recently.

Unveiling Outlook Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	syntone ventures llc	11.4%	2,776,867	SC 13D/A
Apr 08, 2024	great point partners llc	9.99%	2,231,324	SC 13G
Mar 28, 2024	velan capital investment management lp	5.6%	1,250,000	SC 13G
Mar 28, 2024	tang capital partners lp	9.99%	2,215,851	SC 13G
Mar 20, 2024	gms ventures & investments	37.0%	9,266,645	SC 13D/A
Jan 31, 2024	tenshi healthcare pte. ltd.	6.4%	16,637,024	SC 13D/A
Nov 29, 2023	tenshi healthcare pte. ltd.	7.4%	19,351,493	SC 13D/A
Feb 21, 2023	hope jason	7.8%	2e+07	SC 13G/A
Dec 29, 2022	gms ventures & investments	27.9%	71,277,519	SC 13D/A
Jul 08, 2022	tenshi healthcare pte. ltd.	10.2%	22,982,529	SC 13D/A

Recent SEC filings of Outlook Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	8-K	Current Report
Apr 26, 2024	S-3	S-3
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	SC 13D/A	13D - Major Acquisition
Apr 16, 2024	D	D
Apr 15, 2024	8-K	Current Report
Apr 12, 2024	8-K	Current Report
Apr 12, 2024	424B5	Prospectus Filed
Apr 08, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	EFFECT	EFFECT

Peers (Alternatives to Outlook Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Outlook Therapeutics Inc News

Latest updates

Outlook Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q3
Revenue	902.6%	6.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	3.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00	1.00	0.00	-
Operating Expenses	197.8%	19.00	6.00	8.00	11.00	13.00	8.00	8.00	4.00	6.00	8.00	8.00	18.00	10.00	23.00	4.00	17.00	-	-	-	-
S&GA Expenses	51.7%	3.00	2.00	2.00	3.00	6.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	71.7%	7.00	4.00	6.00	6.00	7.00	6.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-80.6%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-238.7%	-2.63	-0.78	-	-	-0.50	-	-	-3.15	0.00	-	-	0.00	-	500*	0.00	-	-	-	-	-
Earnings Before Taxes	-143.9%	-12.73	-5.22	-10.24	-9.74	-12.70	-8.43	-7.54	-5.07	-5.88	-5.33	-8.05	-19.09	-	-	-	-	-	-	-	-
Net Income	-127.3%	-10.10	-4.44	-10.24	-9.74	-12.20	-8.43	-7.54	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-32.9%	22.00	32.00	44.00	54.00	63.00	29.00	39.00	68.00	79.00	23.00	33.00	45.00	13.00	20.00	30.00	13.00	10.00	17.00	33.00	17.00	19.00
Current Assets	-34.2%	20.00	31.00	43.00	53.00	62.00	28.00	38.00	67.00	77.00	22.00	32.00	44.00	11.00	18.00	28.00	9.00	7.00	14.00	19.00	2.00	2.00
Cash Equivalents	-55.7%	10.00	23.00	34.00	44.00	52.00	17.00	26.00	58.00	70.00	14.00	20.00	37.00	6.00	13.00	24.00	5.00	1.00	8.00	14.00	0.00	0.00
Net PPE	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	3.00	14.00	15.00	16.00
Liabilities	-1.5%	46.00	47.00	50.00	44.00	47.00	20.00	19.00	32.00	30.00	18.00	20.00	24.00	23.00	17.00	19.00	34.00	36.00	28.00	35.00	40.00	40.00
Current Liabilities	-1.6%	46.00	47.00	50.00	44.00	15.00	20.00	18.00	31.00	20.00	7.00	20.00	24.00	12.00	16.00	18.00	24.00	20.00	20.00	23.00	27.00	28.00
Long Term Debt	-	-	-	-	-	-	-	-	13.00	12.00	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.00	1.00	1.00	0.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
Shareholder's Equity	-68.6%	-24.34	-14.44	-	10.00	16.00	9.00	20.00	36.00	49.00	5.00	13.00	21.00	-	3.00	11.00	-	-	-	-	-	-
Retained Earnings	-2.4%	-479	-467	-454	-434	-427	-408	-394	-377	-357	-342	-329	-317	-304	-289	-279	-276	-271	-254	-244	-239	-229
Additional Paid-In Capital	0.3%	452	451	447	442	441	415	412	411	404	346	340	336	292	291	290	255	240	238	238	212	202
Shares Outstanding	0%	13.00	13.00	13.00	13.00	11.00	11.00	10.00	10.00	9.00	9.00	8.00	7.00	6.00	6.00	-	-	-	-	-	-	-
Float	-	-	-	-	180	-	-	-	222	-	-	-	200	-	-	-	20.00	-	-	-	19.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-2.3%	-13,032	-12,741	-13,216	-8,114	-8,901	-10,250	-21,099	-14,334	-10,990	-8,990	-20,192	-11,746	-13,324	-12,077	-5,955	-7,083	-6,673	-5,942	-10,306	-6,259	-9,781
Share Based Compensation	-8.4%	1,273	1,389	1,382	1,383	1,392	1,376	1,368	3,763	1,204	1,405	1,198	1,130	1,155	785	1,359	305	359	205	-31.26	268	872
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1*	-150	-50.14	-236
Cashflow From Financing	-100.1%	-3.18	2,424	3,296	-597	43,845	1,626	-11,303	2,608	66,664	3,775	2,715	43,347	6,357	661	26,156	10,402	-8.29	-68.85	24,329	6,237	8,528

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OTLK Income Statement

2023-12-31

Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 4,529,358	$ 9,862,424
General and administrative	5,793,764	5,825,604
Loss from operations	(10,323,122)	(15,688,028)
Income on equity method investment	(2,548)	(21,505)
Interest expense, net	(188,677)	2,448,591
Loss on extinguishment of debt		577,659
Change in fair value of promissory notes	993,000
Change in fair value of warrant liability	53,342	(30,260)
Net loss	$ (11,178,239)	$ (18,662,513)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (0.04)	$ (0.08)
Net loss per share of common stock, diluted (in dollars per share)	$ (0.04)	$ (0.08)
Weighted average shares outstanding, basic (in shares)	260,257,517	227,410,533
Weighted average shares outstanding, diluted (in shares)	260,257,517	227,410,533

OTLK Balance Sheet

2023-12-31

Consolidated Balance Sheets (unaudited) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 10,356,630	$ 23,391,982
Prepaid expenses and other current assets	10,032,579	7,587,216
Total current assets	20,389,209	30,979,198
Operating lease right-of-use assets, net	14,956	26,172
Equity method investment	796,480	793,932
Other assets	484,320	501,299
Total assets	21,684,965	32,300,601
Current liabilities:
Current portion of long-term debt	36,544,000	35,551,000
Current portion of finance lease liabilities	1,084	4,267
Accounts payable	3,480,326	6,574,523
Accrued expenses	4,086,770	2,745,740
Income taxes payable	1,856,629	1,856,629
Total current liabilities	45,968,809	46,732,159
Warrant liability	59,561	6,219
Total liabilities	46,028,370	46,738,378
Commitments and contingencies (Note 8)
Convertible preferred stock:
Total convertible preferred stock
Stockholders' deficit:
Preferred stock, value
Common stock, par value $0.01 per share; 425,000,000 shares authorized; 260,257,517 shares issued and outstanding at December 31, 2023 and September 30, 2023	2,602,574	2,602,574
Additional paid-in capital	452,150,446	450,877,835
Accumulated deficit	(479,096,425)	(467,918,186)
Total stockholders' deficit	(24,343,405)	(14,437,777)
Total liabilities, convertible preferred stock and stockholders' deficit	21,684,965	32,300,601
Series A convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series A-1 convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series B convertible preferred stock
Stockholders' deficit:
Preferred stock, value

About Outlook Therapeutics Inc

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

CEO	Mr. C. Russell Trenary III
WEBSITE	outlooktherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	17

Outlook Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Outlook Therapeutics Inc? What does OTLK stand for in stocks?

OTLK is the stock ticker symbol of Outlook Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Outlook Therapeutics Inc (OTLK)?

As of Fri May 03 2024, market cap of Outlook Therapeutics Inc is 111.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OTLK stock?

You can check OTLK's fair value in chart for subscribers.

What is the fair value of OTLK stock?

You can check OTLK's fair value in chart for subscribers. The fair value of Outlook Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Outlook Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OTLK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Outlook Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether OTLK is over valued or under valued. Whether Outlook Therapeutics Inc is cheap or expensive depends on the assumptions which impact Outlook Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OTLK.

What is Outlook Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, OTLK's PE ratio (Price to Earnings) is -2.17 and Price to Sales (PS) ratio is 13.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OTLK PE ratio will change depending on the future growth rate expectations of investors.